[Pregnancy and inflammatory myopathies].
In general, pregnancies in women with inflammatory myopathy (IM) in sustained remission have a favourable outcome, whereas those pregnant patients with active IM have an increased risk for foetal loss, intra-uterine growth retardation and/or prematurity. The effect of pregnancy on disease activity is variable. All patients with active IM need to be followed by a multidisciplinary team including obstetricians, rheumatologists and/or internists in close relationship with a neonatal intensive care unit. Maternal disease should be treated with corticosteroids, using the same dosage and regimen as for non-pregnant women and according to the disease activity and severity.
Dimitri
Dalia
D
Service d'Histologie, Centre de Référence des Maladies Neuromusculaires, Garches-Necker-Mondor-Hendaye, INSERM U841, CHU Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France. dalia.dimitri@hmn.aphp.fr
Pagnoux
Christian
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005260:Female; D005313:Fetal Death / Q000209:etiology; D005317:Fetal Growth Retardation / Q000209:etiology; D006801:Humans; D009220:Myositis / Q000517:prevention & control*; D007744:Obstetric Labor Complications / Q000517:prevention & control; D010348:Patient Care Team; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control*; D011256:Pregnancy Outcome; D047928:Premature Birth / Q000209:etiology; D011295:Prenatal Care; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents